secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001683168-25-003513
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q1 2025: net loss $0.9M, revenue $0.6M (+16%), cash $5.2M
-----------------------------------------------------------------------------

- Net loss of ~$0.9M for Q1 2025; revenue increased 16.1% to ~$0.6M from $0.5M in Q1 2024.
- Total operating costs decreased 13.7% to ~$1.5M, primarily due to lower personnel costs after CEO/CSO departures in mid-2024.
- Cash position of $5.2M at quarter end; no guidance or dividend changes.
- Advancing DNase I platform; collaboration with PeriNess for exploratory studies in osteosarcoma, Ewing sarcoma, and pancreatic carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/0001683168-25-003513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-003513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer